The contraction of hepatic stellate cells (HSCs) has a critical role in the regulation of intrahepatic vascular resistance and portal hypertension. Previous studies have confirmed that salvianolic acid B (Sal B) is effective against liver fibrosis. In the present study, we evaluated the effect of Sal B on portal hypertension and on HSCs contractility. Liver cirrhosis was induced in rats by peritoneal injection of dimethylnitrosamine and the portal pressure was measured. HSCs contraction was evaluated by collagen gel contraction assay. Glycerol-urea gel electrophoresis was performed to determine the phosphorylation of myosin light chain 2 (MLC2). F-actin stress fiber polymerization was detected by fluorescein isothiocyanate-labeled phalloidin. Intracellular Ca 2 þ and RhoA signaling activation were also measured. Sal B effectively reduced the portal pressure in DMN-induced cirrhotic rats. It decreased the contraction by endothelin-1 (ET-1)-activated HSCs by B66.5% and caused the disassembly of actin stress fibers and MLC2 dephosphorylation. Although Sal B reduced ET-1-induced intracellular Ca 2 þ increase, blocking Ca 2 þ increase completely by BAPTA-AM, a Ca 2 þ chelator, barely affected the magnitude of contraction. Sal B decreased ET-1-induced RhoA and Rho-associated coiled coil-forming protein kinase (ROCK) II activation by 66.84% and by 76.79%, respectively, and inhibited Thr 696 phosphorylation of MYPT1 by 80.09%. In vivo, Sal B lowers the portal pressure in rats with DMN-induced cirrhosis. In vitro, Sal B attenuates ET-1-induced HSCs contraction by inhibiting the activation of RhoA and ROCK II and the downstream MYPT1 phosphorylation at Thr 696 . We consider Sal B a potential candidate for the pharmacological treatment of portal hypertension.
The contraction of hepatic stellate cells (HSCs) has a critical role in the regulation of intrahepatic vascular resistance and portal hypertension. Previous studies have confirmed that salvianolic acid B (Sal B) is effective against liver fibrosis. In the present study, we evaluated the effect of Sal B on portal hypertension and on HSCs contractility. Liver cirrhosis was induced in rats by peritoneal injection of dimethylnitrosamine and the portal pressure was measured. HSCs contraction was evaluated by collagen gel contraction assay. Glycerol-urea gel electrophoresis was performed to determine the phosphorylation of myosin light chain 2 (MLC2). F-actin stress fiber polymerization was detected by fluorescein isothiocyanate-labeled phalloidin. Intracellular Ca 2 þ and RhoA signaling activation were also measured. Sal B effectively reduced the portal pressure in DMN-induced cirrhotic rats. It decreased the contraction by endothelin-1 (ET-1)-activated HSCs by B66.5% and caused the disassembly of actin stress fibers and MLC2 dephosphorylation. Although Sal B reduced ET-1-induced intracellular Ca 2 þ increase, blocking Ca 2 þ increase completely by BAPTA-AM, a Ca 2 þ chelator, barely affected the magnitude of contraction. Sal B decreased ET-1-induced RhoA and Rho-associated coiled coil-forming protein kinase (ROCK) II activation by 66.84% and by 76.79%, respectively, and inhibited Thr 696 phosphorylation of MYPT1 by 80.09%. In vivo, Sal B lowers the portal pressure in rats with DMN-induced cirrhosis. In vitro, Sal B attenuates ET-1-induced HSCs contraction by inhibiting the activation of RhoA and ROCK II and the downstream MYPT1 phosphorylation at Thr 696 . We consider Sal B a potential candidate for the pharmacological treatment of portal hypertension. The role and regulation of contraction by hepatic stellate cells (HSCs) have been areas of active interest and investigation. These cells residing in the perisinusoidal space of Disse, serve as a major storage of vitamin A in normal liver. During chronic hepatic injury, HSCs undergo a process of transdifferentiation toward a myofibroblast phenotype. They consequently acquire enhanced contractility in response to a number of mediators, including endothelin-1 (ET-1), thrombin, angiotensin II and substance P. Among these, ET-1 is the most potent with abundant expression of ET receptors on HSCs. [1] [2] [3] HSCs regulate intrahepatic vascular resistance by contracting around sinusoid and are regarded as the potential therapeutic targets for the treatment of portal hypertension and liver fibrosis. 1, 4, 5 Considerable efforts have been made to elucidate the signaling mechanisms regulating HSCs contraction. Ca 2 þ /MLCK pathway and RhoA/Rho-associated coiled coil-forming protein kinase (ROCK) pathway are two major and best-studied signaling pathways. 6, 7 Ca 2 þ binds to calmodulin to activate myosin light chain kinase (MLCK), which phosphorylates myosin light chain 2 (MLC2). Moreover, the small G-protein RhoA activates its downstream effector ROCK, which in turn phosphorylates and thereby inactivates myosin light chain phosphatase (MLCP), leading to increased phosphorylation of MLC2. 8 The contractile apparatus is formed together by actin and myosin filaments. MLC2 phosphorylation triggers the activation of actomyosin ATPase, cross-bridge cycling and the subsequent force development. The opposing activities of MLCK and MLCP control the phosphorylation status of MLC2. Currently, the contribution of Ca 2 þ signaling for HSCs contraction has been largely challenged, while RhoA/ROCK pathway is considered as the primary signal transduction pathway that govern the force generation. 9 An ideal drug to treat portal hypertension should be potent to decrease HSCs contractility. Current innovative strategies include delivering ROCK inhibitor Y-27632 directly to HSCs by coupling Y-27632 to carriers. 10 However, this strategy is in experimental development and is not applicable in a clinical setting. Previous studies have also indicated several pharmacological agents that can induce cytoskeleton disassembly and inhibit HSCs to contract. 11, 12 Salvianolic acid B (Sal B) is one of the major water-soluble compounds of Salvia miltiorrhiza, which is widely used in China for the treatment of cardiovascular diseases. 13 Sal B is a potent antioxidant that has significant scavenging effects on oxygen free radicals, protecting against ischemia-reperfusion injuries in the heart and brain. 14 In vitro, it protects hepatocytes from CCl 4 -induced cell damage, through inhibiting lipid peroxidation and eliminating ROS accumulation. 15 Available data also indicated that Sal B is effective against liver fibrosis. 16 However, there have been no reports on the effects of Sal B on portal hypertension. The present study indicates that apart from the antifibrotic effect, Sal B effectively reduces the elevated portal pressure in cirrhotic rats. Moreover, our data show for the first time that Sal B as a natural herb extract effectively reduces HSCs contraction. 
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats (180-200 g) were initially randomized into two groups: control (n ¼ 14) and DMN group (n ¼ 31). The rats in DMN group were injected with DMN (10 mg/kg body weight) intraperitoneally for three consecutive days each week. At the end of the second week, two rats were killed for the fibrosis development assessment. The remaining DMN rats were further randomized into two groups: DMN model group (n ¼ 13) and Sal B group (n ¼ 16). Both groups continued to receive weekly DMN treatment for another 2 weeks in addition to daily administration of either water or Sal B, which were given intragastrically at a dose of 12.5 mg/kg body weight.
Histological Analysis
Liver tissues were fixed in 4% paraformaldehyde and dehydrated in a graded alcohol series. After embedded in paraffin, the tissues were sectioned at 5 mm in thickness and stained with hematoxylin-eosin or sirius red.
Portal Pressure Determination
Portal pressure was measured as described previously. 17 Laparotomy was performed and a PE tube (23 G) was inserted into the ileocolic vein and advanced to the confluence of the portal vein and splenic vein. This cannula was used to monitor portal pressure by a transducer system.
HSCs Isolation
HSCs were isolated from male Sprague-Dawley rats, weighing 400 to 500 g, as described previously. 18 In brief, following sequential in situ liver perfusion with pronase E and collagenase type IV, the resulting cell suspension was fractionated by density gradient centrifugation using Nycodenz solution. Cells were harvested at densities o1.065 g/ml and cultured in DMEM containing 10% fetal bovine serum. Experiments were performed on cells between first and third serial passages using three cultures from independent isolations.
Collagen Gel Contraction assay
Type I collagen was extracted by 0.1% acetic acid solution from rat tail tendons for collagen lattice preparation. 19 A mixture solution containing 1.2 mg/ml of collagen was poured into a 12-well plate and incubated for 1 h at 37 1C to allow gelation. Cells were layered on top of the formed lattices and grown to 90% confluence. After pretreatment with Sal B or/and inhibitors at certain concentrations for 30 min, cells were exposed to 10 À 8 M ET-1. The gels were immediately detached from the walls. Digital photos were obtained at 12-h intervals to monitor the change in lattice area.
Determination of MLC2 Phosphorylation
Control and treated monolayers were processed as described previously. 20 Proteins dissolved in urea sample buffer (20 mM Tris base, 22 mM glycine, 10 mM DTT, 8 M deionized urea and 0.1% bromphenol blue) were separated in glycerol gels (10% acrylamide, 40% glycerol, 20 mM Tris base and 22 mM glycine) and transferred to nitrocellulose membranes. The blots were probed with rabbit anti-MLC2 antibody or mouse anti-Ser 19 -MLC2 phosphospecific antibody, followed by IRDye 680-conjugated goat antirabbit IgG or IRDye 800 CW donkey anti-mouse IgG. The blots were analyzed by Odyssey Infrared Imaging System. The extent of MLC2 phosphorylation was calculated as mol PO 4 / mol MLC2 according the following formula: mol PO 4 
, where nonphosphorylated (nonP), monophosphorylated (monoP) and diphosphorylated (diP) represent the nonP, monoP and diP MLC2, respectively.
F-actin Staining
HSCs grown on glass coverslips were treated with ML-7 (10 À 5 M), Y-27632 (10 À 5 M) or Sal B (10 À 5 M) for 30 min, followed by incubation in media with or without ET-1 (10 À 8 M) for 30 min. After fixation with 3.7% paraformaldehyde, polymerized actin was stained by FITC-labeled phalloidin (5 mg/ml). Images were observed and captured by Olympus fluorescence microscopy.
Fluo-4 Visualization of Intracellular Ca 2 þ
Cells seeded on optical quality glass-bottomed 35-mm dishes were loaded with 5 mM Fluo4/0.04% PluronicF-127 in HBS for 45 min at 37 1C. Cells were then stimulated with ET-1(10 À 8 M) in 1.8 mM Ca 2 þ condition, with or without Sal B or BAPTA pretreatment for 30 min. Fluo-4 fluorescence was excited using a Kr/Ar laser at 488 nm and emitted fluorescence at 515 nm was collected. 9 
MYPT1 Phosphorylation
Equal amounts of cell lysates (50 mg) were loaded on 8% SDS-polyacrylamide gel, separated and transferred to nitrocellulose membranes. The blots were probed with rabbit anti-Thr 696 -MYPT1 or rabbit anti-Thr 850 -MYPT1, followed by horseradish peroxidase-conjugated anti-rabbit IgG. Signals were visualized by enhanced chemiluminescence detection.
RhoA Activation Assay
The activity of RhoA was determined by RhoA activation assay kit following the manufacturer's instructions. 21 Fivehundred micrograms of cell lysates were incubated with 30 mg of glutathione S-transferase (GST)-RBD (fusion protein containing the RhoA-binding domain of Rhotekin) complexed with agarose beads for 2 h at 4 1C with gentle agitation. Bound RhoA was eluted from the beads by boiling each sample in Laemmli reducing buffer. Eluted samples from the beads and total cell lysate were then electrophoresed on 12% SDS-polyacrylamide gel, followed by western blotting using mouse anti-RhoA monoclonal antibody.
ROCK Activation Assay
Five-hundred micrograms of lysates were prepared and immunoprecipitated as described previously by ROCK I or ROCK II monospecific antibody. 22 The beads were suspended in kinase assay buffer (20 mM MOPS, pH 7.2, 25 mM B-glycerophosphate, 5 mM EGTA, 15 mM MgCl 2 and 1 mM DTT) containing 10 mM ATP and 1 mg recombinant MYPT1(654-880), in a total reaction volume of 50 ml. Phosphorylated MYPT1(654-880) were detected by western blotting using anti-Thr 696 -MYPT1 antibody. (Figure 1d ). The data indicate that Sal B treatment significantly reduces the portal hypertension in DMN-induced cirrhotic rats. Moreover, Sal B barely affects the heart rate in normal rats, and slightly increases the carotid artery pressure without showing any statistical significance (Figure 1e ).
Sal B Inhibits ET-1-Induced HSCs Contraction
The purity of isolated rat HSCs was always higher than 95% as assessed by detecting vitamin A auto fluorescence and by characterization of typical retinoid droplets. Figure 2a shows the time-dependent activation of HSCs in culture. The contraction was evaluated using a model in which subcultured cells were grown on top of gel lattices composed of type-1 collagen. The lattice shrinkage in ET-1-treated cells was much stronger than in normal cells, with area 37.10±5.10% versus 76.89±3.84%. Pretreatment with 10 À 5 M ML-7 or 10 À 5 M Y-27632 significantly reduced the capability of HSCs to contract. The areas were 67.01 ± 4.14% and 77.28 ± 2.00%, respectively. 10 À 5 M Sal B led to B66.5% of the contractile activity disappearence, showing an area of 63.58 ± 3.21%. As 10 À 2 M ML-7 stock solution was prepared in dimethylsulfoxide (DMSO), we added a control of 0.1% DMSO that barely affected the lattice shrinkage (Figures 2b and c) . 
Salvianolic acid B lowers portal pressure in cirrhotic rats H Xu et al
Sal B decreased ET-1-induced phosphorylation by 71.9% and by 63.1%, respectively.
Sal B Induces the Disassembly of Actin Stress Fibers
Actin assembly is required for HSCs contractibility. As shown in Figure 3 , control and ET-1-treated cells displayed a polygonal morphology with dense bundles of stress fibers aligning along the major axis of the cell. While treated with ML-7 or Y-27632, the actin polymerization was severely ablated with cells showing arborized appearance. The arborization effect was not reversed by ET-1 stimulation. Sal B also caused the disassembly of stress fibers with a few randomly dispersed actin filaments throughout the cytoplasm.
Sal B Reduces ET-1-Induced Ca 2 þ Increase and Inhibits RhoA Activation We observed that ET-1 elicited an immediate influx in intracellular Ca 2 þ that peaked at 1 min and rapidly returned to basal level within 3 min. Pretreatment of Sal B partially reduced the Ca 2 þ increase induced by ET-1. The Ca 2 þ chelator BAPTA-AM, which was used as a positive control, completely blocked the increase in cytosolic Ca 2 þ . However, Salvianolic acid B lowers portal pressure in cirrhotic rats H Xu et al BAPTA-AM barely affected the magnitude of contraction (Figures 4a and b) . We next evaluated whether Sal B has an inhibitory effect on RhoA signaling pathway. To determine the activity of RhoA, Rhotekin-binding assay was performed using RhoAbinding domain from Rhotekin, a downstream effector of RhoA. This fragment binds only GTP-bound active RhoA, but fails to react with GDP-bound RhoA. The activation was determined by comparing relative proportions of GTPbound RhoA to total RhoA. ET-1 stimulation produced a time-dependent increase in RhoA activity by nearly 1.95-fold over control within 60 s and 5.84-fold at 10 min (Figure 4c ). 10 mg/ml C3 exoenzyme, an ADP-ribose transferase and Sal B decreased ET-1-induced RhoA activation by 69.76% and 66.84%, respectively. The ROCK inhibitor Y-27632 had no significant effect on RhoA activity (Figure 4d ). MLCP is a heterotrimeric protein composed of a 37-kDa catalytic subunit of type 1 protein phosphatase (PP-1c), a110-130-kDa regulatory myosin phosphatase targeting subunit (MYPT1) and a 20-kDa subunit of unknown function. 23 The activity of MLCP is mainly regulated by phosphorylation of the MYPT-1 subunit. Several phosphorylation sites have been identified on MYPT-1, including Thr 696 (133-kDa isoform, human) and Thr 850 (133-kDa isoform, chicken), that can be phosphorylated by ROCK. 24, 25 We showed that MYPT1 from untreated control HSCs exhibited a basal level of phosphorylation at Thr 
DISCUSSION
Our data have been expanded on previous work to demonstrate that Sal B, the most abundant component of Salvia miltiorrhiza, decreases the portal pressure in rats with DMN-induced cirrhosis. Furthermore, Sal B significantly reduces in vitro contraction of ET-1-activated HSCs and inhibits the activation of intracellular RhoA/ROCK II signaling pathway. This is for the first time indicating that Sal B acts directly on HSCs contractility through RhoA inhibition.
HSCs have a pivotal role in modulating intrahepatic vascular resistance by contracting around sinusoid. Apart from the increased HSCs contractility, structural changes such as fibrotic scar tissue and collagen deposition also contribute to increased intrahepatic resistance. Augmented portal blood flow, which results from hyperdynamic circulation in the splanchnic and systemic blood vessels, occurs in a more Cell lysates were separated on 8% SDS-PAGE followed by western blotting using anti-Thr 2 þ chelator, barely affected the magnitude of contraction. This result is consistent with previous study, which indicated that changes in cytosolic Ca 2 þ were neither necessary nor sufficient to provoke HSCs contraction. 9 Our results also showed that Y-27632 and ML-7 significantly blocked the lattice shrinkage by ET-1-activated HSCs. The combined use of ML-7 and Y-27632 had a stronger effect than saturating concentrations of either inhibitor alone, suggesting that MLCK and ROCK have complementary effects on HSCs contraction. However, the apparent contradictory results obtained with ML-7 and BAPTA-AM could not be explained, as Ca 2 þ is thought to regulate contraction by activating MLCK. According to the literature, a proportion of MLCK activity may be mediated in a Ca 2 þ -independent way and would not be ablated by Ca 2 þ -free condition. 26 The Ca 2 þ -independent MLCK activity seems to be strong enough to provoke the force development. Whether there are signaling links between RhoA pathway and MLCK activation are not clear and remains to be further studied.
Sal B significantly decreased ET-1-induced activation of RhoA and downstream effector ROCK II. To date, the role of RhoA signaling in HSCs has been mostly learned by copying that in smooth muscles. Detailed information about the dynamic changes, isoforms or phosphorylation status of functional molecules in this signaling cascade in HSCs is incompletely understood. ROCK I and ROCK II, two isoforms of ROCK, are assumed to perform the same functions. They are highly homologous and phosphorylate the same substrates like MYPT1 or MLC2. 27 Moreover, Y-27632 and other commercially available ROCK inhibitors inhibit the activities of two isoforms with almost equal potency. Only rare studies have drawn distinctions between two isoforms. 28, 29 The present study discloses that the activation of ROCK II is highly regulated while ROCK I activity barely changed upon ET-1 stimulation. They may not have equivalent roles during HSCs contraction. , has been identified as a crucial inhibitory site. 25 Second, Thr 850 may be not an endogenous target of ROCK in HSCs and phosphorylation at this site is dominantly regulated by other kinases.
We consider Sal B an ideal drug to treat portal hypertension. Compared with other pharmacological agents, 11, 12, 30 Sal B not only decreases the portal pressure but also is antifibrotic and decreases the contraction of activated HSCs. The effect of Sal B on HSCs contractility is mainly attributed to the suppression of RhoA/ROCK II pathway, which results in the disassembly of actin stress fibers and MLC2 dephosphorylation. As we mentioned above, Sal B also inhibits the transient increase in cytosolic Ca 2 þ , suggesting that Sal B has a pleiotropic effect on both Ca 2 þ and RhoA signaling pathways. However, the precise molecular target of Sal B remains unclear. As Ca 2 þ and RhoA are located upstream of Ca 2 þ and RhoA signaling cascade, respectively, we speculate that Sal B may affect the interaction of ET-1 and ET-1 receptor. This speculation needs to be further clarified. Considering that BAPTA-AM barely affects the contractility of activated HSCs, we also hypothise that in HSCs, RhoA pathway is able to compensate for the complete blocking of Ca 2 þ to generate sufficient contractile force.
Collectively, our data provide evidence that Sal B lowers the portal pressure in rats with DMN-induced cirrhosis. Sal B also significantly reduces HSCs contractility by inhibiting RhoA/ROCK II activation and the downstream MYPT1 phosphorylation at Thr 696 . We consider Sal B as a potential candidate for the pharmacological treatment of portal hypertension.
